These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8719233)

  • 21. Beta-adrenergic blockers. Choosing among them.
    Vlietstra RE; McGoon MD
    Postgrad Med; 1984 Sep; 76(3):71-3, 76-7, 80. PubMed ID: 6147832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacology of adrenergic-adrenoreceptor-blocking drugs.
    Louis WJ; Taylor H; McNeil JJ; Jarrott B; Rand MJ
    Am Heart J; 1982 Aug; 104(2 Pt 2):407-12. PubMed ID: 6125097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of selected beta-adrenergic blocking agents on sleep stages in spontaneously hypertensive rats.
    Ongini E; Milani S; Marzanatti M; Trampus M; Monopoli A
    J Pharmacol Exp Ther; 1991 Apr; 257(1):114-9. PubMed ID: 1673471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sleep disturbances, nightmares and other possible central nervous disturbances in a population sample of women, with special reference to those on antihypertensive drugs.
    Bengtsson C; Lennartsson J; Lindquist O; Noppa H; Sigurdsson J
    Eur J Clin Pharmacol; 1980; 17(3):173-7. PubMed ID: 6102518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of two adrenergic beta-receptor blockers on the sleep cycle of the cat.
    Hilakivi I; Mäkelä J; Leppävuori A; Putkonen PT
    Med Biol; 1978 Jun; 56(3):138-43. PubMed ID: 28454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans.
    de Mey C; Breithaupt K; Schloos J; Neugebauer G; Palm D; Belz GG
    Clin Pharmacol Ther; 1994 Mar; 55(3):329-37. PubMed ID: 7908256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative inotropic effects and the hydrophobicity of beta-adrenergic blocking agents.
    Harada S; Ban T; Fujita T; Koshiro A
    Arch Int Pharmacodyn Ther; 1981 Aug; 252(2):262-71. PubMed ID: 6118107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers.
    Westerlund A
    Eur J Clin Pharmacol; 1985; 28 Suppl():73-6. PubMed ID: 2865153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melatonin secretion related to side-effects of beta-blockers from the central nervous system.
    Brismar K; Hylander B; Eliasson K; Rössner S; Wetterberg L
    Acta Med Scand; 1988; 223(6):525-30. PubMed ID: 3291558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of beta- and alpha-adrenoceptors in the regulation of the stages of the sleep-waking cycle in the cat.
    Hilakivi I
    Brain Res; 1983 Oct; 277(1):109-18. PubMed ID: 6315136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sleep Disturbances and Nightmares in a Patient Treated with Prazosin.
    Kosari S; Naunton M
    J Clin Sleep Med; 2016 Apr; 12(4):631-2. PubMed ID: 26715405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depression from beta-adrenergic-blocking drugs.
    Salem RB; Stewart RB
    Drug Intell Clin Pharm; 1984 Sep; 18(9):741-2. PubMed ID: 6148227
    [No Abstract]   [Full Text] [Related]  

  • 34. A single point mutation increases the affinity of serotonin 5-HT1D alpha, 5-HT1D beta, 5-HT1E and 5-HT1F receptors for beta-adrenergic antagonists.
    Adham N; Tamm JA; Salon JA; Vaysse PJ; Weinshank RL; Branchek TA
    Neuropharmacology; 1994; 33(3-4):387-91. PubMed ID: 7984276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hallucinations and vivid dreams by use of metoprolol].
    Ahmed AI; van Mierlo PJ; van Waarde JA; Jansen PA
    Tijdschr Psychiatr; 2010; 52(2):117-21. PubMed ID: 20146183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors?
    Hjorth S; Carlsson A
    Eur J Pharmacol; 1986 Sep; 129(1-2):131-8. PubMed ID: 2429847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of beta-adrenergic receptor antagonists on nicotine-induced tail-tremor in rats.
    Suemaru K; Gomita Y; Furuno K; Araki Y
    Pharmacol Biochem Behav; 1993 Sep; 46(1):131-3. PubMed ID: 7902979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. beta-Adrenoceptor blocking agents recognize a subpopulation of serotonin receptors in brain.
    Pazos A; Engel G; Palacios JM
    Brain Res; 1985 Sep; 343(2):403-8. PubMed ID: 2864978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Actual knowledge on beta blocking agents in psychiatry (author's transl)].
    Scharbach H
    Acta Psychiatr Belg; 1978; 78(2):358-73. PubMed ID: 27946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy.
    Wellstein A; Palm D; Belz GG; Butzer R; Polsak R; Pett B
    Eur Heart J; 1987 Dec; 8 Suppl M():3-8. PubMed ID: 2897299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.